Efficacy and safety of fruquintinib in the treatment of poor patients with metastatic gastrointestinal cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16028-e16028
Author(s):  
Yanzhi Cui ◽  
Da Jiang ◽  
Xue Zhang ◽  
Fang Huang ◽  
Shaoshuang Fan ◽  
...  
Keyword(s):  
Side Effects ◽  
Disease Progression ◽  
Adverse Reactions ◽  
Advanced Rectal Cancer ◽  
Symptomatic Treatment ◽  
Metastatic Colon Cancer ◽  
Drug Side Effects ◽  
Efficacy And Safety ◽  
The Common ◽  
Cessation Of Treatment

e16028 Background: To explore the efficacy and safety of fruquintinib in the treatment of poor PS patients with Metastatic colorectal cancer. Methods: The data of patients who were treated with fruquintinib in oncology department of our hospital from December 2018 to Janurary 2020 were analyzed retrospectively. Fruquintinib 5mg/ days, 3 weeks of withdrawal for 1 week, 4 weeks as a course of treatment, until the disease progression, death or voluntary cessation of treatment. When side effects occurred, the corresponding anti-symptomatic treatment can be given, if the drug side effects still intolerable, the drug was reduced to 4mg/ days or stop treatment. The adverse drug reactions were evaluated by CTCAE 4.0. The curative effects were evaluated by RECIST Version 1.1. All patients were followed up once every 28 days until the disease progression, death or voluntary cessation of treatment. Results: A total of 9 patients were included, including 2 patients with right metastatic colon cancer, 3 patients with advanced rectal cancer, the incidence of fruquintinib side effects was 100%, which occurred in the first 2 months of treatmentand was common in grade 1 and 2. The common symptoms were hypertension (100%),hand and foot skin reaction (50%), proteinuria (12.5%), dysphonia (31.4%), etc.Incidence of severe side effects was 12.5%, hypertension. Conclusions: The adverse reactions of fruquintinib often occurred within 2 months of treatment, most of which were grade 1 or 2; the patients can benefit from fruquintinib in physical state and organ function.

scholarly journals Evaluation of medicines advertising in medical journals

2009 ◽  
Vol 45 (2) ◽  
pp. 303-312
Author(s):  
Daliana Maria Berenice de Oliveira Souza ◽  
Suellen Cristiane Medeiros de Lima ◽  
Almária Mariz Batista ◽  
Maria Cleide Ribeiro Dantas de Carvalho
Keyword(s):  
Side Effects ◽  
Adverse Reactions ◽  
Healthcare Professionals ◽  
Scientific Information ◽  
Medical Prescription ◽  
Medical Journals ◽  
Registration Number ◽  
The Common

This work intended to analyze the advertising of medicines requiring medical prescription, divulged into three journals of the neurology and cardiology areas addressed to healthcare professionals. The analysis was based on current legislation, among other criteria, as well as specific literature. The presence of the following items was investigated: registration number, drug name, specific indications, contraindications; cautions and warnings; adverse reactions; possible side effects; posology; legibility of technical-scientific information and bibliographic references, phrases and/or expressions about the medication benefits, as compared to other drugs; safety warnings, healing promises and pictures of people smiling, and the quotations confirmation based on bibliographic references. Among the evaluated legal criteria, it was observed the absence of legibility in technical-scientific information in 85% of advertisements; absence of side effects in 23%; absence of cautions and warnings in 15%; of contraindications in 12.8%; of posology in 6.4%; of registration numbers in 2.7% and of the Common Brazilian Denomination/Common International Denomination (Denominação Comum Brasileira/Denominação Comum Internacional - DCB/DCI) in 0.6%. Out of 130 statements respecting advantages face to others drugs, 23.8% were not confirmed and out of 48 divulged safety messages, 41.7% could not be found in quoted references. The pictures of people smiling was a resource used in 42.2% of advertisements. Out of 1362 references analyzed, 19.7% were not found and 37.1% of quoted affirmations weren't confirmed.

Identifying the causative proteins of similar side effect pairs to explore the common molecular basis of these side effects

2015 ◽  
Vol 11 (7) ◽  
pp. 2060-2067
Author(s):  
Yunfeng Wang ◽  
Xiujie Chen ◽  
Lei Liu ◽  
Yuelong Chen ◽  
Hongzhe Ma ◽  
...  
Keyword(s):  
Public Health ◽  
Side Effects ◽  
Molecular Basis ◽  
Health Concern ◽  
Drug Side Effects ◽  
Drug Reactions ◽  
Public Health Concern ◽  
The Common ◽  
Development Failure ◽  
Common Molecular Basis

Drug side effects, or adverse drug reactions (ADRs), have become a major public health concern and often cause drug development failure and withdrawal.

scholarly journals Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 579
Author(s):  
Bogdan Doroftei ◽  
Alin Ciobica ◽  
Ovidiu-Dumitru Ilie ◽  
Radu Maftei ◽  
Ciprian Ilea
Keyword(s):  
Side Effects ◽  
Severe Acute Respiratory Syndrome ◽  
Adverse Events ◽  
Adverse Reactions ◽  
Age Group ◽  
Efficacy And Safety ◽  
Short Time ◽  
Dose Dependent ◽  
Severe Adverse Reactions ◽  
Age And Sex

Severe Acute Respiratory Syndrome Coronavirus 2 is a novel strain of human beta-coronavirus that has produced over two million deaths and affected one hundred million individuals worldwide. As all the proposed drugs proved to be unstable, inducing side effects, the need to develop a vaccine crystallized in a short time. As a result, we searched the databases for articles in which the authors reported the efficacy and safety of the use of several vaccines vaccines by sex, age group, and frequency of adverse reactions. We identified a total of 19 relevant articles that were discussed throughout this manuscript. We concluded that from all eleven vaccines, three had an efficacy >90% (Pfizer–BioNTech (~95%), Moderna (~94%), and Sputnik V (~92%)) except for Oxford–AstraZeneca (~81%). However, Moderna, Sputnik V, and Oxford–AstraZeneca also alleviate severe adverse reactions, whereas in Pfizer–BioNTech this was not revealed. The remaining five (Convidicea (AD5-nCOV); Johnson & Johnson (Ad26.COV2.S); Sinopharm (BBIBP-CorV); Covaxin (BBV152), and Sinovac (CoronaVac)) were discussed based on their immunogenicity, and safety reported by the recipients since only phases 1 and 2 were conducted without clear evidence published regarding their efficacy. CoviVac and EpiVacCorona have just been approved, which is why no published article could be found. All adverse events reported following the administration of one of the four vaccines ranged from mild to moderate; limited exceptions in which the patients either developed severe forms or died, because most effects were dose-dependent. It can be concluded that aforementioned vaccines are efficient and safe, regardless of age and sex, being well-tolerated by the recipients.

scholarly journals Aflibercept: side effects in focus

2018 ◽  
pp. 18-26
Author(s):  
M. Yu. Fedyanin
Keyword(s):  
Colon Cancer ◽  
Side Effects ◽  
Disease Progression ◽  
Metastatic Colon Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Prevention And Treatment ◽  
Risk Of Disease ◽  
Degrees Of Severity

A new anti-angiogenic drug aflibercept has been authorized as a second-line therapy in patients with metastatic colon cancer. The use of this drug as part of FOLFIRI regimen significantly reduces the risk of disease progression (RR = 0.758, p = 0.00007). At the same time, the additional use of aflibercept in the VELOUR study led to the development of side effects of 3-4 degrees of severity in 83.5% of patients. In this case, the use of aflibercept in combination with FOLFIRI is not only associated with complications that are typical for anti-angiogenic drugs, but also with a high percentage of cases of diarrhea and neutropenia. In this regard, the oncologist should understand the pathogenesis, the methods for prevention and treatment of complications associated with the use of aflibercept. These particular aspects are highlighted is this review.

Methylphenidate Reaction

PEDIATRICS ◽  
1975 ◽  
Vol 55 (6) ◽  
pp. 895-896
Author(s):  
Esther K. Sleator
Keyword(s):  
Side Effects ◽  
Psychotropic Drug ◽  
Psychotropic Drugs ◽  
Adverse Reactions ◽  
Research Center ◽  
Drug Side Effects ◽  
Research Subjects ◽  
Hyperkinetic Syndrome ◽  
Idiosyncratic Reaction

Shader and DiMascio, in their book Psychotropic Drug Side Effects (1970), state "In spite of the fact that methylphenidate is one of the few psychotropic drugs that is widely available and recommended for use in the treatment of the hyperkinetic syndrome in children, remarkably few reports document adverse reactions to the drug." This is true of our experience at Children's Research Center. However, out of a total of 130 research subjects, one manifested a striking idiosyncratic reaction.

scholarly journals Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0246463
Author(s):  
Xiaohong Chen ◽  
Lifang Feng ◽  
Hui Yao ◽  
Luhong Yang ◽  
Yuan Qin
Keyword(s):  
Side Effects ◽  
Cohort Studies ◽  
Large Scale ◽  
Meta Analysis ◽  
Systemic Review ◽  
Hyperinsulinemic Hypoglycemia ◽  
Efficacy And Safety ◽  
Federal Drug Administration ◽  
The Common ◽  
Line Drug

Diazoxide is the first-line drug for treating hyperinsulinism and the only pharmacological agent approved for hyperinsulinism by the Federal Drug Administration. This systemic review and meta-analysis aimed to investigate the efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia (HH). The meta-analysis of the efficacy and safety of diazoxide in treating HH was performed by searching relevant studies in the PubMed, Embase, and Cochrane databases. The findings were summarized, and the pooled effect size and its 95% confidence interval (CI) were calculated. A total of 6 cohort studies, involving 1142 participants, met the inclusion criteria. Among the cohort studies, the pooled estimate of the response rate of diazoxide therapy was 71% (95% CI 50%–93%, Pheterogeneity< 0.001, I2 = 98.3%, Peffect< 0.001). The common side effects were hypertrichosis (45%), fluid retention (20%), gastrointestinal reaction (13%), edema (11%), and neutropenia (9%). Other adverse events included pulmonary hypertension (2%) and thrombocytopenia (2%). This meta-analysis suggested that diazoxide was potentially useful in HH management; however, it had some side effects, which needed careful monitoring. Furthermore, well-designed large-scale studies, such as randomized controlled trials, might be necessary in the future to obtain more evidence.

Side Effects of Chemotherapy and Cancer Treatment in Tertiary Care Teaching Hospital

2016 ◽  
Vol 2 (1) ◽  
pp. 62-78
Author(s):  
. Hemraj ◽  
Raj Kumar ◽  
Sourabh Kosey ◽  
Amit Sharma ◽  
Nalini Negi
Keyword(s):  
Side Effects ◽  
Tertiary Care ◽  
Cross Sectional Study ◽  
Informational Needs ◽  
Cross Sectional ◽  
Clinical Pharmacists ◽  
Medical College ◽  
Related Information ◽  
The Common ◽  
Chemotherapy Patients

To determine the most common physical side effects experienced by local chemotherapy patients. Their perceptions of these side effects and informational needs from clinical pharmacists were also evaluated. This was a single center, observational cross-sectional study conducted at department of General Surgery, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab. A face to face interview was conducted. Information collected included chemotherapy related side effects after last chemotherapy experience, the most worrisome side effects, overlooked by healthcare professionals and the preferred method, amount and source of receiving related information. In this study, hundred patients were enrolled out of them 48 were male and 52 were female. When differential calculations was done, common side effects or adverse effects of chemotherapy in the patients of breast, lung cancer, Ovarian Cancer, Colon cancer, Prostate cancer, Lymphoma Cancer, Cervix cancer where there is much irregular medicine intake 57.4% may be due to common problem of joint pain reported by all the patients under study, with the consecutive problem of nausea and vomiting. The high prevalence of chemotherapy related side effects among local patients is a major concern and findings of their perceptions and informational needs may serve as a valuable guide for clinical pharmacists and physicians to help in side effect management. This study shows the common problems reported by the patients when they are suffering from cancer condition, according to their incidence perceptions as experienced by the patient, this will allow the physician and clinical pharmacist to effectively counsel and manage the common symptoms as reported prior to its occurrence in the patient, so that withdrawal can be checked.

EFFICACY OF CARVEDILOL COMBINED WITH ENDOSCOPIC VARICEAL LIGATION IN THE PREVENTION OF RECURRENT VARICEAL BLEEDING IN PATIENTS OF CIRRHOSIS

2016 ◽  
pp. 23-30
Author(s):  
Van Huy Tran ◽  
Thi Ngoc Diep Bui
Keyword(s):  
Side Effects ◽  
Beta Blocker ◽  
Variceal Bleeding ◽  
Poor Prognosis ◽  
Oesophageal Varices ◽  
Endoscopic Variceal Ligation ◽  
Efficacy And Safety ◽  
Orthostatic Hypertension ◽  
Key Words Carvedilol ◽  
Very High

Background: The recurrent variceal bleeding is still very high with a very poor prognosis. The combination of a non-selective beta-blocker and endoscopic variceal ligation (EVL) is still a standard therapy for the prevention, but many patients showed no response to propranolol. Carvedilol is a new, non-selective beta-blocker having intrinsic alpha-blocker activity, but the data about the efficacy and safety of carvedilol is still very limited. This study is aimed at assessing the efficacy and safety of carvedilol combined with EVL in the prevention of recurrent variceal bleeding. Patients and methods: 33 patients having variceal bleeding were enrolled. All patients received carvedilol and were performed the EVL until variceal eradication. All the patients were followed after 9 months. Results: rate of variceal eradication of oesophageal varices was 87.88%; the recurrence rate of variceal bleeding was 12.12% after 9 months. The side effects of carvedilol were rare and not severe, including vertiges, headache, and orthostatic hypertension. Conclusion: Carvedilol combined with EVL appeared as a relatively safe and effective in the prevention of recurrent variceal bleeding in patients of cirrhosis. Key words: carvedilol, variceal bleeding, EVL

Sign in / Sign up

Export Citation Format

Share Document